Zymeworks opened lower at $28.92, compared with its previous close of $29.07. In the last trading session, the stock traded between $26.59 and $29.03. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Zymeworks is now worth
$ 134.06
Giving a profit of
$ 34.06 (34.06%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-2.46 (-8.46%)
Day High
$29.03
Day Low
$26.59
Day Open
$28.92
Prev Close
$29.07
Volume
9,76,605
1W Return
-14.00%
1M Return
4.98%
3M Return
9.45%
6M Return
10.74%
1Y Return
35.21%
Fundamentals
Market Cap ($ Mn)
1,837
PE Ratio
-
PB Ratio
25.31
PEG Ratio
-
ROE
-25.56%
ROCE
-26.38%
EPS (TTM)
$2.42
Investment Returns
1 Week
-14.00%
1 Month
4.98%
3 Months
9.45%
6 Months
10.74%
9 Months
16.56%
Financials
Quarterly
All values in $ Mn
27.1
Mar 25
48.7
Jun 25
27.6
Sep 25
2.5
Dec 25
4.6
Jun 26
256.5
Sep 26
Updates
10Nov
HC Wainwright raises Zymeworks price target to $56, maintains Buy
HC Wainwright & Co. maintains a Buy rating on Zymeworks Inc. The price target is raised from $55 to $56 by analyst Robert Burns. The stock trades on the NASDAQ exchange under the ticker ZYME.
2 days ago
10Nov
Zymeworks raises FY26 sales guidance to $337M-$351M vs est
Zymeworks raises FY2026 sales guidance to $337.000 million-$351.000 million. New guidance exceeds consensus estimate of $302.672 million. Q3 EPS of $2.28 beats estimate by 4.59%, reversing prior year loss. Q3 revenue jumps 828.73% YoY to $256.46 million.
3 days ago
15Oct
Zymeworks to report Q3FY27 results Nov 9, skips call for investor chats
Zymeworks will report Q3 2026 financial results on November 9, 2026. No conference call or webcast planned for the earnings release. Management will attend four investor conferences in November 2026. Events include Wolfe Research, Stifel, Truist, and Jefferies conferences.
28 days ago
29Sep
Citigroup raises Zymeworks price target to $39, maintains Buy
Citigroup raised the price target for Zymeworks to $39. The previous price target was set at $38. Analyst Yigal Nochomovitz maintained a Buy rating. The price target increase represents a $1 adjustment.
1mo ago
28Sep
Zymeworks finalizes Theravance deal, sets FY26 revenue at $278M-$292M
Finalized acquisition of Theravance Biopharma on Monday. FY26 revenue guidance set at $278M-$292M, missing consensus. Adjusted EBITDA guided between $114M and $128M. Accessed $600M in non-dilutive financing via non-recourse notes. Shares rose 2.34% to $27.14 following announcement.
1mo ago
11Aug
Zymeworks to present at four major healthcare investor conferences in September
Zymeworks Inc. will present at four key investor conferences in September 2026, including events by Wells Fargo, Citi, Morgan Stanley, and H.C. Wainwright. Management will hold fireside chats and one-on-one meetings to discuss its licensed asset portfolio, led by Ziihera, and its development pipeline for cancer and autoimmune therapies.
